Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameClover Bio-B
Stock Code02197
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities一家處於臨床試驗階段的全球性生物技術公司,致力於為傳染性疾病以及癌症及自身免疫性疾病開發新型疫苗及生物治療候選產品。
Listing Date2021-11-05
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國四川省成都市中國(四川)自由貿易試驗區成都高新區天府大道北段1480號高新孵化園1號樓B5-19
Business Address (Hong Kong)香港銅鑼灣希慎道33號利園一期19樓1901室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.cloverbiopharma.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 13.38 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 6,690
Par ValueTo be extracted
Offer Period2021-10-25 to 2021-10-28
Global Offering Shares150,000,000 shares
HK Public Offer Shares (Initial)15,000,000 shares (10.0%)
Public Offer Lots (Initial)30,000lots (Pool A15,000lots,Pool B15,000lots)
International Placing Shares (Initial)135,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,158,114,723 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share53.7%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 2,007,000,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 6,690
2 lots 1,000 HK$ 13,380
3 lots 1,500 HK$ 20,070
4 lots 2,000 HK$ 26,760
5 lots 2,500 HK$ 33,450
6 lots 3,000 HK$ 40,140
7 lots 3,500 HK$ 46,830
8 lots 4,000 HK$ 53,520
9 lots 4,500 HK$ 60,210
10 lots 5,000 HK$ 66,900
12 lots 6,000 HK$ 80,280
14 lots 7,000 HK$ 93,660
16 lots 8,000 HK$ 107,040
18 lots 9,000 HK$ 120,420
20 lots 10,000 HK$ 133,800
30 lots 15,000 HK$ 200,700
40 lots 20,000 HK$ 267,600
50 lots 25,000 HK$ 334,500
60 lots 30,000 HK$ 401,400
70 lots 35,000 HK$ 468,300
80 lots 40,000 HK$ 535,200
90 lots 45,000 HK$ 602,100
100 lots 50,000 HK$ 669,000
120 lots 60,000 HK$ 802,800
140 lots 70,000 HK$ 936,600
160 lots 80,000 HK$ 1,070,400
180 lots 90,000 HK$ 1,204,200
200 lots 100,000 HK$ 1,338,000
300 lots 150,000 HK$ 2,007,000
400 lots 200,000 HK$ 2,676,000
500 lots 250,000 HK$ 3,345,000
600 lots 300,000 HK$ 4,014,000
700 lots 350,000 HK$ 4,683,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
800 lots 400,000 HK$ 5,352,000
900 lots 450,000 HK$ 6,021,000
1,000 lots 500,000 HK$ 6,690,000
1,200 lots 600,000 HK$ 8,028,000
1,400 lots 700,000 HK$ 9,366,000
2,000 lots 1,000,000 HK$ 13,380,000
4,000 lots 2,000,000 HK$ 26,760,000
15,000 lots 7,500,000 HK$ 100,350,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 2.67B
Est. Threshold HK$ 9.69B
Analysis Result HK market cap below threshold, need +263%

Valuation & Financials

Market Cap (at Offer Price)HK$ 15,229,208,607
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不适用(公司处于亏损状态)
Profit/Loss Status亏损约人民币912.9百万元
Period-End Cash Balance人民币516.2百万元
Listing Expenses~HK$ 135,300,000
Listing Expenses / Funds Raised~6.74%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20192020
Other income and gains, net 16,90824,341
Administrative expenses -45,979
Profit before tax -48,469
Profit for the year -48,309
Income Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 12.98
First Day OpenHK$ 13.38
First Day Change-2.99%
First Day Volume33982000.0
First Day Turnover448171000.0
Use of Proceeds
約65%,或1,215.6百萬港元將用于我們核心產品及相關產品的研發、生產及商業化; 約22.5%,或420.8百萬港元將用于我們管線中其他產品的研發、生產及商業化; 約12.5%,或233.8百萬港元將用作營運資金及其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017
Joint Bookrunners (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017
Joint Lead Managers (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Aranda Investments Pte. Ltd. 155,589,330 HKD — 7.80% — 6 months 2022-05-05
2 Athos Asia Event Driven Master Fund 116,686,980 HKD — 5.80% — 6 months 2022-05-05
3 Hillhouse Funds 171,143,580 HKD — 8.50% — 6 months 2022-05-05
4 Oceanpine Capital Management Limited 116,686,980 HKD — 5.80% — 6 months 2022-05-05
5 OrbiMed Funds 194,484,990 HKD — 9.70% — 6 months 2022-05-05
6 Rock Springs Capital Master Fund LP 147,808,860 HKD — 7.40% — 6 months 2022-05-05
7 Springhill Master Fund Limited 77,791,320 HKD — 3.90% — 6 months 2022-05-05
8 Superstring Capital Master Fund LP 58,343,490 HKD — 2.90% — 6 months 2022-05-05
9 Toroa Master Fund 38,895,660 HKD — 1.90% — 6 months 2022-05-05

Directors & Management

PositionChinese nameEnglish Name
Chairman梁朋—
Company SecretaryBrian KREX、馮寶婷—
No director data available.

Major Shareholders

Major Shareholders & Holdings梁博士持股約17.83%、梁果先生持股約1.51%、JNRY約8.53%、AUT-XXI約6.29%、Aranda約8.53%、上海天合約6.04%、汪世碧女士約8.69%、Elasa約6.31%。
About this page

This page shows Clover Bio-B (02197) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect